Coverage
-
June 19, 2013
A Pennsylvania federal judge Wednesday gave final approval to a $35 million settlement ending a class action alleging GlaxoSmithKline PLC used improper means to block its rivals from bringing generic versions of its allergy medication Flonase to market.
6 other articles on this case.
View all »